CLBack of Napkin
ClearPoint Neuro, Inc. CLPT
ClearPoint Neuro sells $42.3M of trailing revenue for about twelve times sales while losing more each quarter than the quarter before.
The setup turns on whether the gene therapies its sixty biopharma partners are pushing toward the FDA actually get approved, because commercial approvals are the only thing that converts this from a story stock into a royalty on drugs delivered into the brain.
CLPT · price with moving averages
Source: market data.
The business
ClearPoint makes the hardware, software and disposables that let a neurosurgeon steer a catheter or cannula to a precise spot in the brain inside an MRI scanner. Hospitals buy the navigation systems, then buy single-use kits every case. The second business is the option: most cell and gene therapies aimed at the brain need exactly this kind of delivery, so drug developers design their trials around ClearPoint's platform, and roughly sixty of them are partners today. If a partner's drug is approved, every commercial dose shipped needs ClearPoint disposables and support, written into the way the therapy is administered. That trial-by-trial lock-in is the moat. Last November it bought IRRAS, a Swedish maker of fluid-management catheters, adding a second product line into the same neuro operating rooms.
Inside the complete Back of Napkin
- 01The business
- 02The numbers
- 03Management
- 04How it fails or surprises you
- 05The shape of the payoff
- 06Closing thoughts
- 07Methodology
Continue with CLPT
Get the complete Back of Napkin free.
Choose this as your free complete report. No card required.
Read the complete reportAlready a member? Sign in


